Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-GU1: ivonescimab + enfortumab vedotin versus pembrolizumab + enfortumab vedotin in first-line advanced urothelial carcinoma
CTR20263988Phase 3Active
- Sponsor
- CTTQ-Akeso
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab, enfortumab vedotin, pembrolizumab in transitional cell carcinoma (TCC), sponsored by CTTQ-Akeso. Started Oct 2026; status: active.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20263988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263988.